Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data

Journal of the Royal Society Interface

Volumn 12, Issue 104, 2015, Pages

  Sacks Davis, Rachel ^a,b   McBryde, Emma ^a,c,d   Grebely, Jason ^e   Hellard, Margaret ^a,b   Vickerman, Peter ^f  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Epidemiology; Hepatitis C infection; Monte Carlo Markov chain

Indexed keywords

BAYESIAN NETWORKS; CHAINS; EPIDEMIOLOGY; MARKOV PROCESSES; MONTE CARLO METHODS; PROBABILITY; STATISTICAL TESTS; VIRUSES;

BAYESIAN ESTIMATE; HEPATITIS C; HEPATITIS C VIRUS; MARKOV CHAIN MONTE-CARLO; MONTE CARLO MARKOV CHAIN; OBSERVATIONAL STUDY; PRIOR PROBABILITY; SIMULATION STUDIES;

UNCERTAINTY ANALYSIS;

ARTICLE; BAYES THEOREM; DISEASE CLEARANCE; DISEASE PREDISPOSITION; HEPATITIS C; HUMAN; INFECTION RATE; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; OBSERVATIONAL STUDY; PROBABILITY; REINFECTION; VALIDITY; ALGORITHM; COMPUTER SIMULATION; GENETICS; HEPACIVIRUS; MARKOV CHAIN; RECURRENT DISEASE; REPRODUCIBILITY; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

VIRUS RNA;

ALGORITHMS; BAYES THEOREM; COMPUTER SIMULATION; HEPACIVIRUS; HEPATITIS C; HUMANS; MARKOV CHAINS; MODELS, STATISTICAL; MONTE CARLO METHOD; PROBABILITY; RECURRENCE; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923239859     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2014.1197     Document Type: Article

References (44)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013 Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333-1342. (doi:10. 1002/hep. 26141)
2. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. 2011 Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378, 571-583. (doi:10. 1016/s0140-6736(11)61097-0)
3. Micallef JM, Kaldor JM, Dore GJ. 2006 Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 13, 34-41. (doi:10. 1111/j. 1365-2893. 2005. 00651. x.)
4. Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME. 2013 Current and emerging antiviral treatments for hepatitis C infection. Br. J. Clin. Pharmacol. 75, 931-943. (doi:10. 1111/j. 1365-2125. 2012. 04419. x.)
5. Sacks-Davis R et al. 2013 High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS ONE 8, e80216. (doi:10. 1371/ journal. pone. 0080216)
6. Grebely J et al. 2012 Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 55, 1058-1069. (doi:10. 1002/hep. 24754)
7. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, Thomas DL, Cox AL. 2010 Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138, 315-324. (doi:10. 1053/j. gastro. 2009. 09. 017)
8. Page K et al. 2013 Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin. Infect. Dis. 56, 405-413. (doi:10. 1093/cid/cis921)
9. Pham ST, Bull RA, Bennett JM, Rawlinson WD, Dore GJ, Lloyd AR, White PA. 2010 Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology 52, 1564-1572. (doi:10. 1002/hep. 23885)
10. van de Laar TJW, Molenkamp R, van den Berg C, Schinkel J, Beld MGHM, Prins M, Coutinho RA, Bruisten SM. 2009 Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J. Hepatol. 51, 667-674. (doi:10. 1016/ j. jhep. 2009. 05. 027)
11. Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, van der Meer JT, Schinkel J. 2011 Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 25, F21-F27. (doi:10. 1097/QAD. 0b013e32834bac44)
12. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. 2006 Hepatitis C virus reinfection in injection drug users. Hepatology 44, 1139-1145. (doi:10. 1002/hep. 21376)
13. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL. 2002 Protection against persistence of hepatitis C. Lancet 359, 1478-1483. (doi:10. 1016/S0140-6736(02)08435-0)
14. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, Kaldor JM, White PA, Dore GJ. 2007 High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J. Viral Hepat. 14, 413-418. (doi:10. 1111/j. 1365-2893. 2006. 00812. x)
15. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, Drummer H, Hellard M. 2008 High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48, 1746-1752. (doi:10. 1002/hep. 22534)
16. Currie SL, Ryan JC, Tracy D, Wright TL, George S, McQuaid R, Kim M, Shen H, Monto A. 2008 A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. [Erratum in Drug Alcohol Depend. 2008 96, 192. ] Drug Alcohol Depend. 93, 148-154. (doi:10. 1016/j. drugalcdep. 2007. 09. 011)
17. Larsen C et al. 2011 Gaining greater insight into HCV emergence in HIV-infected men who have sex with men: the HEPAIG study. PLoS ONE 6, e29322. (doi:10. 1371/journal. pone. 0029322)
18. Martin TCS, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, Gazzard BG, Nelson M. 2013 HCV reinfection incidence and treatment outcome among HIV-positive MSM in London. AIDS 27, 2551-2557. (doi:10. 1097/QAD. 1090b1013 e32836381cc)
19. Cox AL, Thomas DL. 2013 Hepatitis C virus vaccines among people who inject drugs. Clin. Infect. Dis. 57, S46-S50. (doi:10. 1093/cid/cit329)
20. Page K et al. 2009 Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J. Infect. Dis. 200, 1216-1226. (doi:10. 1086/605947)
21. Vickerman P et al. 2012 The more you look the more you find-effects of hepatitis C virus testing interval on re-infection incidence and clearance: implications for future vaccine study design. J. Infect. Dis. 205, 1342-1350. (doi:10. 1093/infdis/ jis213)
22. Grebely J, Thomas DL, Dore GJ. 2009 HCV reinfection studies and the door to vaccine development. J. Hepatol. 51, 628-631. (doi:10. 1016/j. jhep. 2009. 07. 002)
23. Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK. 2009 Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J. Infect. 58, 375-382. (doi:10. 1016/j. jinf. 2009. 02. 014)
24. Lloyd AL. 2001 Destabilization of epidemic models with the inclusion of realistic distributions of infectious periods. Proc. R. Soc. Lond. B 268, 985-993. (doi:10. 1098/rspb. 2001. 1599)
25. Hastings W. 1970 Monte Carlo sampling methods using Markov chains and their applications. Biometrika 57, 97-109. (doi:10. 1093/biomet/57. 1. 97)
26. Amin J, Law MG, Micallef J, Jauncey M, Van Beek I, Kaldor JM, Dore GJ. 2007 Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol. Infect. 135, 144-150. (doi:10. 1017/S0950268806006388)
27. Prince AM, Brotman B, Lee D-H, Pfahler W, Tricoche N, Andrus L, Shata MT. 2005 Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J. Infect. Dis. 192, 1701-1709. (doi:10. 1086/496889)
28. Scott JD, Gretch DR. 2007 Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA 297, 724-732. (doi:10. 1001/jama. 297. 7. 724)
29. R Development Core Team. 2011 R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
30. Goldstein BY, Steinberg JK, Aynalem G, Kerndt PR. 2011 High chlamydia and gonorrhea incidence and reinfection among performers in the adult film industry. Sex. Transm. Dis. 38, 644-648. (doi:10. 1097/OLQ. 0b013e318214e408)
31. Das A et al. 2013 High rates of reinfection and incidence of bacterial sexually transmitted infections in a cohort of female sex workers from two Indian cities: need for different STI control strategies? Sex. Transm. Infect. 89, 5-10. (doi:10. 1136/sextrans-2012-050472)
32. Nankabirwa J, Wandera B, Kiwanuka N, Staedke SG, Kamya MR, Brooker SJ. 2013 Asymptomatic plasmodium infection and cognition among primary schoolchildren in a high malaria transmission setting in Uganda. Am. J. Trop. Med. Hyg. 88, 1102-1108. (doi:10. 4269/ajtmh. 12-0633)
33. Versteegh F, Mertens P, De Melker HE, Roord JJ, Schellekens JFP, Teunis PFM. 2005 Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiol. Infect. 133, 737-748. (doi:10. 1017/S0950268805003833)
34. Kelly PJ, Lim LL-Y. 2000 Survival analysis for recurrent event data: an application to childhood infectious diseases. Stat. Med. 19, 13-33. (doi:10. 1002/(SICI)1097-0258(20000115)19:1,13::AIDSIM279. 3. 0. CO;2-5)
35. Cook RJ, Lawless JF. 2007 The statistical analysis of recurrent events. New York, NY: Springer.
36. Mosley JW et al. 2008 The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J. Viral Hepat. 15, 120-128. (doi:10. 1111/j. 1365-2893. 2007. 00900. x.)
37. Price MJ, Ades AE, Angelis DD, Welton NJ, Macleod J, Soldan K, Turner K, Simms I, Horner PJ. 2013 Mixture-of-exponentials models to explain heterogeneity in studies of the duration of Chlamydia trachomatis infection. Stat. Med. 32, 1547-1560. (doi:10. 1002/sim. 5603)
38. Heijne JC, Herzog SA, Althaus CL, Tao G, Kent CK, Low N. 2013 Insights into the timing of repeated testing after treatment for Chlamydia trachomatis: data and modelling study. Sex. Transm. Infect. 89, 57-62. (doi:10. 1136/sextrans-2011-050468)
39. Koelle DM, Wald A. 2000 Herpes simplex virus: the importance of asymptomatic shedding. J. Antimicrob. Chemother. 45, 1-8. (doi:10. 1093/jac/45. suppl-4. 1)
40. Tronstein E, Johnston C, Huang M, Selke S, Magaret A, Warren T, Corey L, Wald A. 2011 Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 305, 1441-1449. (doi:10. 1001/jama. 2011. 420)
41. Wilson DP. 2012 HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med. 9, e1001231. (doi:10. 1371/journal. pmed. 1001231)
42. Thomas DL et al. 2009 Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801. (doi:10. 1038/nature08463)
43. Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. 2007 Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can. J. Gastroenterol. 21, 447-451.
44. Kim AY et al. 2011 Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 140, 686-696. (doi:10. 1053/j. gastro. 2010. 09. 042)